Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma

Overview of attention for article published in Cancer Research Communications, February 2025

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (56th percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 4 X users

bluesky: 2 Bluesky users

Readers on

mendeley: 9 Mendeley

So far, Altmetric has seen 4 Bluesky posts from 2 Bluesky users, with an upper bound of 135 followers.

BD Biosciences's resource, RRID:AB_1727528, was just reported to be used in "Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melano…". We appreciate the author's support …

Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma scientiasalut.gencat.cat/handle/11351... #ScientiaVH

Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma aacrjournals.org/cancerrescom... #hvhebron #onco [Text complet]

Phase 1b study of immunocytokine simlukafusp alfa (FAP-IL2v) combined with pembrolizumab for treatment of advanced and/or metastatic melanoma aacrjournals.org/cancerrescom... #hvhebron #onco [Text complet]

This page shows the most recent Bluesky posts that mention this research output. Click here to find out how to access more activity.